Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were ...

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, ...

Shares of Scholar Rock Holding ( SRRK 13.36%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

Shares of Scholar Rock climbed after the company disclosed what it called positive results from a Phase 2 study assessing its drug for weight loss. Shares rose 12% to $35.01 in pre-market trading ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...